AAPGNasdaqPharmaceutical PreparationsFiscal year ends December 31

ASCENTAGE PHARMA GROUP INTERNATIONAL

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 29, 2026

$15.36−0.01 (-0.07%)

Close on Oct 19, 2026

ASCENTAGE PHARMA GROUP INTERNATIONAL income statement

AnnualQuarterlyTTM

CNY USD

Millions of CNY, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31
Revenue	574	981	222	210
Cost of Revenue	49	29	31	22
Gross Profit	525	952	191	188
Research & Development	1,137	947	707	743
General & Administrative	246	187	181	171
Interest Expense	54	64	96	53
Income from Equity Investments	0.31	-0.28	1.08	-0.28
Pretax Income	-1,236	-395	-933	-887
Income Tax Expense	6.94	10	-7.15	-4.25
Net Income incl. Noncontrolling Interests	-1,243	-406	-926	-883
Minority Interest in Earnings	-0.22	-0.25	-0.08	–
Net Income	-1,243	-405	-926	-883
EPS (Basic)(per share)	-3.49	-1.34	-3.28	-3.35
EPS (Diluted)(per share)	-3.49	-1.34	-3.28	-3.35
Shares Outstanding (Basic, Weighted)(shares)	356	302	282	264
Shares Outstanding (Diluted, Weighted)(shares)	356	302	282	264

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Dec 31, 2025

Profitability, FY2025

Gross margin: 91.5%
Operating margin: –
Net margin: -216.5%
Return on equity, FY2025: -156.5%

Financial strength

Current ratio: 1.79
Debt to equity: 1.50
Debt to assets: –
Cash to current liabilities: 72.8%

Valuation

P/E ratio: –
Price to sales: –
Price to book: –
Dividend yield: –

Valuation ratios need the share price and fill in once daily prices are connected.